Amgen 2002 Annual Report Download - page 5

Download and view the complete annual report

Please find page 5 of the 2002 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 72

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72

Page 3
1999 1998 1997 1996 1995 1994 1993
$3,042.8 $2,514.4 $2,219.8 $2,088.2 $1,818.6 $1,549.6 $1,306.3
297.3 203.8 181.2 151.6 121.3 98.3 67.5
3,340.1 2,718.2 2,401.0 2,239.8 1,939.9 1,647.9 1,373.8
402.1 345.2 300.8 283.2 272.9 238.1 220.0
822.8 663.3 630.8 528.3 451.7 323.6 255.3
654.3 515.4 483.8 470.6 418.4 359.8 328.4
—————116.4 —
———————
(49.0) (23.0) 157.0 — — — (13.9)
1,096.4 863.2 644.3 679.8 537.7 319.7 383.3
1.02 0.82 0.59 0.61 0.48 0.29 0.33
———————
1999 1998 1997 1996 1995 1994 1993
$4,077.6 $3,672.2 $3,110.2 $2,765.6 $2,432.8 $1,994.1 $1,765.5
223.0 223.0 229.0 59.0 177.2 183.4 181.2
3,023.5 2,562.2 2,139.3 1,906.3 1,671.8 1,274.3 1,172.0
93 94 95 96 97 98 99 00 01 02
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
Research and Development Expenses
($ in millions)
$1,116.6
865.0
845.0
822.8
663.3
630.8
528.3
451.7
323.6
255.3
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
93 94 95 96 97 98 99 00 01 02
10,118
7,682
7,326
6,355
5,585
5,372
4,709
4,084
3,396
3,109
Amgen Staff
(4)
Other items, net in 2002 includes: 1) a benefit of $151.2 million related to the Company’s arbitration with Johnson & Johnson, 2) a benefit of $40.1 million related to a
recovery of certain expenses accrued in 2001 related to finalizing the termination of collaboration agreements with various third parties, and 3) a charitable contribution of
$50 million to the Amgen Foundation. Other items, net in 2001 primarily relates to the costs of terminating collaboration agreements with various third parties. Other
items, net in 2000 includes a benefit of $73.9 million related to a legal proceeding with Johnson & Johnson, and a charitable contribution of $25 million to the Amgen
Foundation. Other items, net in other years is comprised of benefits and expenses related to various legal proceedings. See Note 4 to the Consolidated Financial Statements
for further discussion of other items, net for 2002, 2001, and 2000.
(5)
In July 2002, Amgen acquired all of the outstanding common stock of Immunex for approximately $17.8 billion. See Note 3 to the Consolidated Financial Statements for
further discussion of the acquisition and the related purchase price allocation.
(6)
In March 2002, Amgen issued zero-coupon, senior convertible notes with a face amount at maturity of $3.95 billion. See Note 8 to the Consolidated Financial Statements
for further discussion of the terms of the convertible notes.